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Oncology as a specialty appears to be growing exponentially, with
establishment of specialist clinicians working in dedicated centres,
armed with ever increasing options for treatment. Even so, little
more than 10% of all adult cancers are currently cured and overall
mortality rate has hardly changed over the last half century (Bailar
and Gornik, 1997). Noteworthy, yet perhaps forgivable, is the fact
that this dismal figure is rarely emphasized to the public. It is as
painful to ourselves as to our patients to accept failure. Media
headlines heralding early research findings as a ‘cancer cure on the
horizon’ reflect the outcome we all wish to encounter in our life-
time, yet in reality, few such preclinical ‘breakthroughs’ achieve
meaningful clinical benefit. Thus, most of the treatment admini-
stered for cancer will not cure our patients. We describe their
treatment as ‘palliative’ in nature. But do we really know what
form of palliation is achieved with treatment?
This book entitled, Cancer: How worthwhile is non-curative
treatment?, edited by ML Slevin and T Tate, attempts to address
this question. The editors make the point that considerable confu-
sion and uncertainty surrounds the potential benefits and harms of
treating patients with non-curable cancer. Thus, with the assistance
of a series of specialist oncologists, a fairly stringent review has
been conducted of the independent roles of surgery, radiotherapy
and chemotherapy in palliating disease. It is no easy task, since, as
many of the chapters independently discuss, high quality data in
defining end points of palliation are hard to find.
These three key treatment modalities now occupy an unques-
tioned position in being considered to modify the natural
behaviour of advanced cancer and so achieve effective palliation
of disease. Yet, we need to address the question, just exactly what
is achieved, and at what cost? The post-war experience when
administering the first nitrogen mustards to lymphoma patients
taught our predecessors important lessons which still plague us
today: tumours regrow following visible tumour eradication and
other solid tumours are far less chemo- and radio-sensitive. So this
book has tried to identify what can be achieved by non-curative
treatments in the context of the common cancers.
Derived from the Latin meaning ‘cloak’, ‘to palliate’ literally
means to ‘alleviate without curing’. Cancer specialists can classify
cancers into those which are curable or incurable, and so offer our
patients treatment with curative or palliative intent. The first
problem the surgeons encounter is that most patients are operated
on with ‘curative intent’, yet the statistical facts confirm that more
often than not this is not achieved. The salient lesson from this
observation is that surgeons need to discuss this difficult issue with
their patients at the time of definitive surgery and then liase closely
with their oncology colleagues, since multidisciplinary team
working can benefit us all. The second problem is that few clinical
trials of cancer surgery in the palliative setting have been under-
taken. The third point is that while novel techniques such as lasers,
cryoprobes and stents are now being introduced into clinical
practice, evaluation in terms of symptom control is scarce.
The evidence of benefit with non-curative radiotherapy fares
little better! The aims of palliative radiotherapy are varied. It may
be implemented to achieve local control of asymptomatic disease
with a view to improving quality of or prolong life. Alternatively,
it may be used to alleviate symptoms. Well conducted, prospective
and/or randomized trials to evaluate the former of these end
points, are sadly lacking overall, despite the valiant efforts by
Drs Sebag-Montefiore and Arnott to define the evidence-base in
the context of, for example, gastrointestinal tract cancers. In
contrast, the chapter describing radiotherapy for controlling
symptomatic bone metastases is excellent instruction to the reader.
The point is made that perhaps many patients too often think the
aim of their treatment is prolongation of survival. These chapters
should be read by oncologists who perhaps think likewise!
The aims of systemic therapy are equally variable: to delay or
prevent tumour growth, prolong life, or relieve symptoms.
Chemotherapy is, however, perhaps more often prescribed in hope
than in expectation of benefit. Alison Jones’ chapter on non-
curative treatment of breast cancer honestly describes how
chemotherapy became standard practice without undergoing
clinical trials compared against best supportive care, yet only
40–60% of women will respond to first-line therapy and few
patients will gain prolonged survival. What then is the value of this
treatment? Can we define benefit in terms of quality of life as
opposed to quantity of life? Alternatively, shouldn’t we be
working towards selecting patients more likely to respond? In the
current climate, we also need to address the health economics of
treatment and scrutinize carefully the validity of second and third
line therapies in incurable patients. Is there a level of subtle
coercion which causes doctors to administer probably futile
chemotherapy at times when more appropriate support measures
might be in the patient’s interest? These rather provocative
questions can only be properly answered if we know the true value
of the palliative treatments being administered.
The chapter I recommend to you is Mike Cullen’s account of
how chemotherapy has been developed in the context of non-
small-cell lung cancer (NSCLC). Clearly, most people would
accept an amount of personal inconvenience and discomfort if the
treatment intention is to cure, but what if a patient’s life
expectancy is around 12 months, despite treatment? Certainly,
concerns regarding treatment-related toxicity, duration and practi-
cality of administration have and still do result in failure of referral
of cancer patients to specialist oncologists. It is therefore up to us
to provide the evidence of what can be achieved by palliation of
disease. In this chapter, Dr Cullen defines the goal of palliation in
terms of the balance between quantity and quality of life. Quality
of life must be considered in terms of practicalities of receiving
treatment – hospital visits can be exhausting – and treatment-
related side-effects must be weighed against the likelihood of
controlling disease-related symptoms.
Since systemic therapy is probably the only modality likely to
influence the natural history of NSCLC, it is right to pursue this
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Sir
We read with great interest the article by Tjalma et al (1998). The
authors have investigated the angiogenic parameters in patients with
cervical carcinoma whose menstrual states are not defined. The
human endometrium undergoes a complex process of vascular and
glandular proliferation, differentiation and regeneration with each
menstrual cycle in preparation for implantation. Vascular endothe-
lial growth factor (VEGF) is an endothelial cell-specific angiogenic
protein that appears to play an important role in both physiological
and pathological neovascularization (Goodger and Rogers, 1995;
Shifren et al, 1996). As for the physiological neovascularization,
there are two or three different endometrial angiogenic events
during the human menstrual cycle, a post-menstrual repair, a
mid–late proliferative growth and a lesser mid-secretory activity that
may be associated with spiral arteriole growth (Rogers et al, 1992).
The new capillaries formed in a malignant tumour are structurally
similar to the capillaries growing during physiological neovascular-
ization (Folkman and Klagsbrun, 1987). Patients with cervical carci-
noma who are within the reproductive period of their lives, from
menarche to menopause, the latter possessing wide variations in the
age at which it occurs (Cunningham et al, 1993), still do menstruate,
especially in the early stages. So a biopsy specimen obtained during,
just before, or immediately after menstruation could be misleading.
In this retrospective histopathological analysis, microvessel counts
(MVC), which are representative of angiogenesis, are found to be
either increased or decreased independent of menstruation. In
conclusion, since the important impact of menstruation, physiolog-
ical neovascularization, on MVC has not been mentioned it can be
claimed that the results of this study must have been affected.
I œH G￿ll￿ and S Marangoz
Hacettepe University, Institute of Oncology,
Sihhiye, 06100, Ankara, Turkey
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line of approach. However, a meta-analysis of randomized trials of
chemotherapy versus best supportive care has suggested marginal
survival benefit of around 6 weeks. These data alone cannot justify
chemotherapy as standard care. The data that clinch the argument
in favour of treatment are comparison of patient symptomatology
before and after a period of MIC chemotherapy. Dr Cullen
describes the efforts to collect and analyse patient symptom data in
the MIC trials, which was no easy task. Yet the data are priceless
and the graphic presentation of symptom improvement with treat-
ment needs no statistical number to justify itself. This chapter is a
must for specialist registrars and consultants alike.
Overall, the style of this book is not optimal – segregation of
treatment modalities normally considered together in a multi-
disciplinary approach makes reading rather cumbersome. The
small font size and lack of illustrations makes it heavy reading for
students, but the book is probably better dipped into than read
cover-to-cover. Trainees are advised to bear in mind the speed of
change in cancer management. For example, oral etoposide no
longer has a place in treating poor-risk patients with SCLC.
Having read from cover-to-cover, this book leaves me with the
distinct feeling of unease that oncology is practised predominantly
as an art rather than a science in our country. Perhaps this is the
best we can do at the current time, given our present evidence-
base. As is emphasized many times in various chapters, there is an
urgent need for more prospective studies to measure the benefit
of non-curative treatment, both in terms of patient symptoms,
toxicity and quality of life, alongside conventional end points of
response and survival. This requires good quality clinical trials
undertaken systematically by all practising oncologists – our
service base must also be a data collection exercise if we are to
properly define the role of the treatments we use on a daily basis.
A recent clinical trial undertaken in the USA attempted to compare
the role of palliative radiotherapy to stenting in advanced
oesophageal cancer. The study closed with 276 patients entered
during a period of time when at least 2700 new cases of this
disease would have been diagnosed. This is simply unacceptable.
Finally, palliation of disease may constitute one or more of a
number of goals. We must make it our duty both to clearly define
these goals, and to know with some certainty the likely outcomes
achieved with treatments offered to our patients. A requirement for
education and constant reeducation must be our highest priority,
since only in an atmosphere of knowledge can we achieve
complete honesty in delivering the best care for our patients today
and strive towards developing better treatments in the future.
REFERENCE
Bailar JC and Gornik HL (1997) Cancer undefeated. N Engl J Med 336: 1569–1574
P de Takats
Department of Medical Oncology,
Addenbrooke￿s Hospital,
Hills Road, Cambridge CB2 2QQ
Letter to the Editor
Quantification and prognostic relevance of angiogenic
parameters in invasive cervical cancer